Molecular Templates, Inc.

MT-3724

Advancing a Differentiated Treatment Option

Molecular Templates’ lead compound, MT-3724, is a first generation ETB that targets CD20, a B-cell marker that is expressed in 90 percent of B-cell non-Hodgkin’s lymphoma (NHL).

Program Partner Indication (Target) Preclinical Phase 1 Phase 2 Phase 3 Next Stage
MT-3724 DLBCL monotherapy (CD20)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
DLBCL combination with GEMOX (CD20)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
DLBCL combination with Lenalidomide (CD20)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
a) Potential for Phase 2 to be pivotal in relapsed/refractory setting as monotherapy
Completed
In-progress
Planning
Phase 2 is potentially pivotal

Potential Benefits

Promising Signals of Activity in DLBCL

  • MT-3724 is the first clinical agent to efficiently internalize CD20, a canonical non-internalizing receptor.
  • Since high serum levels of Rituxan® (RTX) inhibits MT-3724 activity, patients with high serum RTX levels were excluded.
  • The Phase 1/1b study was conducted in heavily pretreated DLBCL patients and monotherapy activity was observed.
  • MT-3724 appears in early clinical studies to have a favorable tolerability profile. The maximum tolerated dose was established at 50 mcg/kg. Dose-limiting toxicities (DLTs) were non-life threatening grade 2/3 events and grade 2 capillary leak syndrome.

Addressing Non-Hodgkin Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most prevalent type of non-Hodgkin lymphoma (NHL) in the U.S. and worldwide. This aggressive, fast-growing NHL affects B-lymphocytes, a type of white blood cell that creates antibodies to fight infections.

People Affected by NHL

~77,240

People in the U.S. expected to be diagnosed with NHL in 20201.

~19,940

Estimated number of people who will die from the disease in 20201.

Current Treatment Options

Radiation, chemotherapy +/- antibody treatment (Rituxan®), CAR-T, and stem cell transplant.

Unmet Medical Needs in NHL

  • Certain disease subtypes with poor prognosis.
  • Patients who have relapsed or who have failed chemotherapy or antibody treatments.
  • Treatment-naïve patients who cannot tolerate or who are ineligible for chemotherapy.

1 American Cancer Society. Accessed from: https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html on April 27, 2020.

Clinical Overview

Enrollment ended for the Phase 1/1b monotherapy study of MT-3724 in the first quarter of 2019. In this study, 27 patients were treated across a range of doses (5 mcg/kg-100mcg/kg) and 50 mcg/kg was identified as the maximum tolerated dose. Final data from this study was presented at the American Society of Hematology 2019 Annual Meeting.

We are conducting a Phase 2 monotherapy study of MT-3724 in relapsed/refractory DLBCL. We believe this study has the potential to serve as a registration study. We are also conducting two Phase 2 studies in earlier lines of DLBCL, one with MT-3724 in combination with chemotherapy (gemcitabine and oxaliplatin) and the other with MT-3724 in combination with Revlimid®.

View Clinical Trials
Posters & Presentations

Posters & Presentations

To learn more about the MT-3724 candidate, explore our research publications.

View Posters & Presentations